| Literature DB >> 32904955 |
Edgar García-Cruz1, Daniel Manzur-Sandoval1, Rodrigo Gopar-Nieto2, Adriana L Murillo-Ochoa1, Gabriela Bejarano-Alva1, Gustavo Rojas-Velasco1, Rolando J Álvarez-Álvarez1, Francisco Baranda-Tovar3.
Abstract
Objective: The current coronavirus disease 2019 (COVID-19 outbreak) demands an increased need for hospitalizations in emergency departments (EDs) and critical care units. Owing to refractory hypoxemia, prone position ventilation has been used more frequently and patients will need repeated hemodynamic assessments. Our main objective was to show the feasibility of obtaining images to measure multiple parameters with transthoracic echocardiography during the prone position ventilation.Entities:
Keywords: echocardiography; mechanical ventilation; prone position
Year: 2020 PMID: 32904955 PMCID: PMC7461552 DOI: 10.1002/emp2.12239
Source DB: PubMed Journal: J Am Coll Emerg Physicians Open ISSN: 2688-1152
FIGURE 1Performing an echocardiogram on a human model in prone position. See text for explanation of the position and measurements
FIGURE 2Evaluation of right and left ventricular function in mechanically ventilated patients in prone position. Panel A: Apical 4‐chamber view. Panel B: right ventricle/left ventricle ratio. Panel C: tricuspid peak systolic S wave tissue Doppler velocity (S wave).Panel D: tricuspid annular plane systolic excursion (TAPSE). Panel E: left ventricular outflow tract velocity integral time (LVOT VTI). Panel F: mitral annular plane systolic excursion (MAPSE). Panel G: E velocity of mitral inflow filling pattern. Panel H: lateral e′ velocity
Patients clinical characteristics
| Case | BMI | Age | Comorbidities | Presenting symptoms | Chest X‐ray | paFiO2 | IOT‐ Prono time | Treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | 29.1 | 39 | Overweight | Diarrhea, fever, dry cough, and dyspnea | Bilateral ground‐glass opacification | 67 | 24h | Lung protective and prone position ventilation vasopressors, steroids, broad‐spectrum antibiotics, antiviral and anticoagulation. |
| 2 | 28.3 | 66 | Overweight and type 2 diabetes | Arthralgias, fever and dyspnea | Cardiomegaly and patchy peripheral left mid to lower lung opacities | 80 | 24h | Lung protective and prone position ventilation, antiviral and anticoagulation |
| 3 | 24.5 | 56 | Smoking | Odynophagia and dyspnea | Diffuse interstitial involvement, predominantly peripheral | 111 | 72h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 4 | 33.1 | 50 | Obesity | Odynophagia, fever, and dyspnea | Severe interstitial thickening at lower lobes | 91 | 48h | Lung protective and prone position ventilation, lopinavir/ritonavir, systemic steroids, and anticoagulation |
| 5 | 32.4 | 63 | Overweight, gout, and dyslipidemia | Dry cough, odynophagia fever, and dyspnea | Ground‐glass opacification at lung bases | 93 | 12h | Lung protective and prone position ventilation, hydroxychloroquine, azithromycin, anticoagulation, steroids, and hemodialysis |
| 6 | 35.1 | 64 | Obesity | Arthralgias, odynophagia, fever, and dyspnea | Severe peripheral interstitial involvementpredominantlyat lower lobes | 52 | 6h | Lung protective and prone position ventilation, systemic steroids, and hemodialysis |
| 7 | 24.9 | 64 | Type 2 diabetes and hypertension | Lipothymy, AV block, and fever | Peripheralbilateral ground‐glass opacification | 76 | 72h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 8 | 31.1 | 79 | Obesity, type 2 diabetes, and hypertension | Arthralgia, odynophagia, fever, and dyspnea | Diffuse interstitial involvement, predominantly peripheral | 111 | 48h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 9 | 36.3 | 50 | Obesity, hypertension, hyperuricemia, gout, and dyslipidemia | Odynophagia fever and dyspnea severe | Diffuse ground glass opacities predominantly at lung bases | 96 | 5 days | Lung protective and prone position ventilation, systemic steroids, and hemodialysis |
| 10 | 24.4 | 71 | Hypertension, dyslipidemia, and ischemic heart disease | Dry cough, fever, and dyspnea | Cardiomegaly and bilateral ground‐glass opacification | 53 | 72h | Lung protective and prone position ventilation, antiviral and anticoagulation |
| 11 | 23.6 | 70 | Type 2 diabetes | Dry cough, fever, and dyspnea | Peripheral interstitial involvement and right basal consolidation | 85 | 12h | Lung protective and prone position ventilation, hydroxychloroquine, azithromycin, and anticoagulation |
| 12 | 30.2 | 52 | Obesity | Dry cough, fever, and dyspnea | Severe interstitial involvement predominantly in lung bases | 65 | 8h | Lung protective and prone position ventilation, antiviral, and anticoagulation |
| 13 | 22.9 | 66 | Type 2 diabetes | Asthenia, fever, and dyspnea | Severe interstitial involvement predominantly peripheral | 79 | 48h | Lung protective and prone position ventilation, systemic steroids, antiviral, and anticoagulation |
| 14 | 24.1 | 69 | Alcoholism | Dry cough, fever, and dyspnea | Diffuse interstitial involvement | 66 | 12h | Lung protective and prone position ventilation, antiviral, and anticoagulation |
| 15 | 34.4 | 57 | Obesity | Productive cough, fever, and dyspnea | Bilateral diffuse ground‐glass opacities | 100 | 4h | Lung protective and prone position ventilation, antiviral, and anticoagulation |
Echocardiographic measurements during the prone position ventilation
| Patient (P) | TAPSE | S′ wave | RV basal diameter | RV/LV ratio | LVOT VTI | LVOT VTI variability | LVF | E/e´ | MAPSE | PE |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 21 | 13 | 41 | 0.8 | 17 | NO | N | 11 | 14 | NO |
| 2 | 23 | 13 | 40 | 0.7 | 15 | YES | MR | 5 | 12 | NO |
| 3 | NA | NA | NA | NA | 23 | NO | MR | 5 | 11 | NO |
| 4 | 18 | 14 | 38 | 0.7 | 23 | NO | N | 10 | 18 | NO |
| 5 | 18 | 13 | 40 | 0.8 | 16 | NO | N | 8 | 13 | NO |
| 6 | 23 | 11 | 41 | 0.9 | 25 | YES | N | 9 | 17 | NO |
| 7 | 19 | 15 | 43 | 0.9 | 18 | NO | MR | 12 | 11 | NO |
| 8 | 27 | 19 | 39 | 0.8 | 19 | NO | N | 8 | 15 | NO |
| 9 | 22 | 11 | 35 | 0.85 | 17 | NO | N | 13 | 13.5 | NO |
| 10 | 14 | 9 | 37 | 0.8 | 13 | NO | MR | 15 | 9 | NO |
| 11 | 13 | 8 | 35 | 0.7 | 13 | YES | MR | 16 | 9 | NO |
| 12 | 16 | 11 | 39 | 0.8 | 17 | NO | N | 10 | 14 | NO |
| 13 | 18 | 9 | 43 | 0.9 | 14 | NO | MR | 10 | 10 | NO |
| 14 | 18 | 14 | 39 | 0.8 | 15 | YES | N | 5 | 15 | NO |
| 15 | 17 | 13 | 40 | 0.9 | 15 | NO | N | 8 | 13 | NO |
LV, left ventricular; LVF, left ventricular qualitative systolic function; LVOT, left ventricular outflow tract; MAPSE, mitral annular plane systolic excursion; MR, moderately reduced); N, normal; NA, not available; PE, pericardial effusion; RV, right ventricular; S wave, tricuspid peak systolic S wave tissue Doppler velocity; TAPSE, tricuspid annular plane systolic excursion; VTI, velocity‐time integral.
Normal values: TAPSE ≥17 mm, S wave ≥9.5 cm/s, RV basal diameter <42 mm, RV/LV ratio <1, LVOT VTI 18–22 cm, LVOT VTI variability ≥ 12%, MAPSE ≥13 mm.